$NTHI

Heshmatpour Amir F purchased $59K of NTHI

Heshmatpour Amir F (CEO, President) purchased 15,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.91 ($3.79–$4.37) across 2 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · Heshmatpour Amir F
Published Aug 17, 2026, 10:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTHI
Bullish
low confidence
Mentioned
$NTHI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHIBullishLow
01

Why it matters

The newest fact is the CEO/President’s open-market purchase of 15,000 shares at $3.7883 to $4.3733 between 2026-08-14 and 2026-08-17, with the filing timestamp on 2026-08-17.

02

Market read

Traders may note the insider buy as a small sentiment input, but it does not provide new guidance, financial results, or regulatory/contract catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, compensation timing, or whether the purchase was part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for NEONC Technologies Holdings, Inc. (NTHI).

Company-level read

Ticker impact

$NTHIBullishLow confidence
Context

CEO/President Heshmatpour Amir F bought $58,579 of NTHI shares in two open-market trades, per a fresh SEC Form 4 filed today.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by larger actions or company-specific news.

Evidence & confidence

The filing is a routine Form 4 insider purchase with modest dollar value and no accompanying operational or financial disclosure.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases under open-market Form 4s can be routine liquidity or diversification-related and may not reflect a change in business outlook.

Key entities

  • NEONC Technologies Holdings, Inc.

    Subject of the insider transaction disclosure (Form 4).

  • Heshmatpour Amir F

    CEO, President, and officer/director/10% owner who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.